scispace - formally typeset
M

Michael D. Blum

Researcher at Merck & Co.

Publications -  7
Citations -  767

Michael D. Blum is an academic researcher from Merck & Co.. The author has contributed to research in topics: Vaccination & Pneumococcal polysaccharide vaccine. The author has an hindex of 6, co-authored 6 publications receiving 651 citations.

Papers
More filters
Journal ArticleDOI

Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults.

TL;DR: Both primary vaccination and revaccination with PN23 induce antibody responses that persist during 5 years of observation, and baseline geometric mean concentrations of IgG were higher in revaccinations than primary vaccination subjects.
Journal ArticleDOI

Fever after Immunization: Current Concepts and Improved Future Scientific Understanding

TL;DR: By standardizing the definition and means of assessment of fever in vaccine safety studies, thereby permitting comparability of data, it is hoped that an improved understanding of its importance as an AEFI is arrived at.
Journal ArticleDOI

A comparison of multiple regimens of pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine and pneumococcal polysaccharide vaccine in toddlers.

TL;DR: A single dose of PCV at 12-18 months of age primed for responses to booster doses of either PCV or PN23 12 months later, resulting in more frequent injection site pain and erythema than boosting with PCV, yet higher antibody concentrations for most of the serotypes tested.